Pascale A Cohen

List of Publications by Year
in descending order

37 papers	2,069 citations	279798 23 h-index	345221 36 g-index
38 all docs	38 docs citations	38 times ranked	3706 citing authors

#	Article	IF	Citations
1	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncology, The, 2014, 15, 267-274.	10.7	351
2	Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors. Endocrine Reviews, 2011, 32, 597-622.	20.1	244
3	Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 29-57.	1.6	136
4	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer, 2010, 126, 545-562.	5.1	110
5	ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion. Cancer Research, 2012, 72, 3593-3606.	0.9	107
6	Monitoring Cellular Responses to Listeria monocytogenes with Oligonucleotide Arrays. Journal of Biological Chemistry, 2000, 275, 11181-11190.	3.4	106
7	Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer, 2003, 3, 13.	2.6	77
8	CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19525-19530.	7.1	73
9	Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins. Journal of Biological Chemistry, 1997, 272, 30937-30944.	3.4	71
10	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Research, 2015, 17, 13.	5.0	69
11	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene–expression levels. Cancer Science, 2008, 99, 1992-2003.	3.9	66
12	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology, 2009, 42, 87-103.	2.5	65
13	Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene, 1998, 17, 2445-2456.	5.9	57
14	A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Research, 2008, 10, R88.	5.0	54
15	The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget, 2015, 6, 41566-41581.	1.8	50
16	Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochemical and Biophysical Research Communications, 2008, 375, 308-314.	2.1	42
17	ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Molecular Cancer, 2010, 9, 291.	19.2	42
18	Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of *de novo* or acquired resistance and importance of combining the allosteric Akt inhibitor MK–2206 with an aromatase inhibitor. International Journal of Cancer, 2013, 133, 1589-1602.	5.1	42

#	ARTICLE	IF	CITATIONS
19	The critical role of the <scp>ZNF217</scp> oncogene in promoting breast cancer metastasis to the bone. Journal of Pathology, 2017, 242, 73-89.	4.5	42
20	Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling. Cell Death and Differentiation, 2017, 24, 155-166.	11.2	39
21	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. Molecular Oncology, 2014, 8, 1441-1457.	4.6	32
22	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor Â expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocrine-Related Cancer, 2008, 15, 125-138.	3.1	30
23	LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers. Cancer Research, 2016, 76, 3541-3552.	0.9	28
24	The Natural Mutation Y248C of Human Angiotensinogen Leads to Abnormal Glycosylation and Altered Immunological Recognition of the Protein. Journal of Biological Chemistry, 1996, 271, 9838-9844.	3.4	16
25	Intrabodies: Targeting scFv Expression to Eukaryotic Intracellular Compartments. , 2002, 178, 367-378.		15
26	Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein. FEBS Letters, 1999, 463, 179-184.	2.8	13
27	Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 2773.	4.1	13
28	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. Frontiers in Oncology, 2020, 10, 712.	2.8	13
29	Interaction of the octapeptide angiotensin II with a high-affinity single-chain Fv and with peptides derived from the antibody paratope. Journal of Immunological Methods, 2001, 254, 147-160.	1.4	11
30	The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Frontiers in Pharmacology, 2019, 10, 667.	3.5	11
31	Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer. Frontiers in Pharmacology, 2018, 9, 1581.	3.5	11
32	Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours. Computers in Biology and Medicine, 2013, 43, 334-341.	7.0	8
33	New monoclonal antibodies directed against the propart segment of human prorenin as a tool for the exploration of prorenin conformation. Journal of Immunological Methods, 1995, 184, 91-100.	1.4	7
34	MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors. International Journal of Breast Cancer, 2011, 2011, 1-6.	1.2	6
35	The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DXÂ® Recurrence Score in ER-Positive Invasive Breast Cancers. Frontiers in Pharmacology, 2019, 10, 524.	3.5	3
36	Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Frontiers in Oncology, 2021, 11, 647269.	2.8	2

#	Article	IF	Citations
37	Environmental pollutants-dependent molecular pathways and carcinogenesis. BioDiscovery, 0, 22, .	0.1	0